R W Wieten1, A Goorhuis2, E F F Jonker3, G J de Bree2, A W de Visser3, P J J van Genderen4, E B M Remmerswaal5, I J M Ten Berge6, L G Visser3, M P Grobusch2, E M M van Leeuwen5. 1. Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: rosannewieten@icloud.com. 2. Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 3. Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands. 4. Institute for Tropical Diseases, Harbour Hospital, Rotterdam, the Netherlands. 5. Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 6. Renal Transplant Unit, Division of Internal Medicine, Academic Medical Center, the Netherlands.
Abstract
BACKGROUND: The 17D live attenuated yellow fever (YF) vaccine is contra-indicated in immune-compromised individuals and may elicit a suboptimal immunologic response. The aim of this study is to assess whether long-term immune responses against the YF vaccine are impaired in immune-compromised patients. MATERIALS AND METHODS: Fifteen patients using different immunosuppressive drugs and 30 healthy individuals vaccinated 0-22 years ago were included. The serological response was measured using the plaque reduction neutralization test (PRNT). CD8(+) and CD4(+) T-cell responses were measured following proliferation and re-stimulation with YFV peptide pools. Phenotypic characteristics and cytokine responses of CD8(+) T-cells were determined using class I tetramers. RESULTS: The geometric mean titre of neutralizing antibodies was not different between the groups (p = 0.77). The presence of YFV-specific CD4(+) and CD8(+) T-cell did not differ between patients and healthy individuals (15/15, 100.0% vs. 29/30, 96.7%, p = 0.475). Time since vaccination correlated negatively with the number of YFV-specific CD8(+) T-cells (r = -0.66, p = 0.0045). Percentages of early-differentiated memory cells increased (r = 0.67, p = 0.017) over time. CONCLUSION: These results imply that YF vaccination is effective despite certain immunosuppressive drug regimens. An early-differentiated memory-like phenotype persisted, which is associated with effective expansion upon re-encounter with antigen, suggesting a potent memory T-cell pool remains.
BACKGROUND: The 17D live attenuated yellow fever (YF) vaccine is contra-indicated in immune-compromised individuals and may elicit a suboptimal immunologic response. The aim of this study is to assess whether long-term immune responses against the YF vaccine are impaired in immune-compromised patients. MATERIALS AND METHODS: Fifteen patients using different immunosuppressive drugs and 30 healthy individuals vaccinated 0-22 years ago were included. The serological response was measured using the plaque reduction neutralization test (PRNT). CD8(+) and CD4(+) T-cell responses were measured following proliferation and re-stimulation with YFV peptide pools. Phenotypic characteristics and cytokine responses of CD8(+) T-cells were determined using class I tetramers. RESULTS: The geometric mean titre of neutralizing antibodies was not different between the groups (p = 0.77). The presence of YFV-specific CD4(+) and CD8(+) T-cell did not differ between patients and healthy individuals (15/15, 100.0% vs. 29/30, 96.7%, p = 0.475). Time since vaccination correlated negatively with the number of YFV-specific CD8(+) T-cells (r = -0.66, p = 0.0045). Percentages of early-differentiated memory cells increased (r = 0.67, p = 0.017) over time. CONCLUSION: These results imply that YF vaccination is effective despite certain immunosuppressive drug regimens. An early-differentiated memory-like phenotype persisted, which is associated with effective expansion upon re-encounter with antigen, suggesting a potent memory T-cell pool remains.
Authors: Ismael Artur da Costa-Rocha; Ketty Lysie Libardi Lira Machado; Ana Carolina Campi-Azevedo; Andréa Teixeira-Carvalho; Vanessa Peruhype-Magalhães; Sheila Maria Barbosa de Lima; Emily Hime Miranda; Gisela Freitas Trindade; Thays Zanon Casagrande; Samira Tatiyama Miyamoto; Sávio Carvalho Deotti; Rafaela Villa Real Barbosa; Priscila Costa Martins Rocha; Erica Vieira Serrano; Valquiria Garcia Dinis; Sônia Alves Gouvêa; Maria Bernadete Renoldi de Oliveira Gavi; Lidia Balarini da Silva; Ruben Horst Duque; Ana Paula Espíndula Gianordoli; Maria de Fatima Bissoli; Maria da Penha Gomes Gouvea; Lauro Ferreira da Silva Pinto-Neto; Ana Paula Neves Burian; Francieli Fontana Sutile Tardetti Fantinato; Gecilmara Salviato Pileggi; Licia Maria Henrique da Mota; Valéria Valim; Olindo Assis Martins-Filho Journal: Sci Rep Date: 2021-05-17 Impact factor: 4.379
Authors: Joseph Kamtchum-Tatuene; Benjamin L Makepeace; Laura Benjamin; Matthew Baylis; Tom Solomon Journal: Curr Opin Infect Dis Date: 2017-02 Impact factor: 4.915